title: Reversible Pharmacological Induction of Motor Symptoms in MPTP-Treated Mice at the Presymptomatic Stage of Parkinsonism: Potential Use for Early Diagnosis of Parkinson's Disease.
abstract: A crucial event in the pathogenesis of Parkinson's disease is the death of dopaminergic neurons of the nigrostriatal system, which are responsible for the regulation of motor function. Motor symptoms first appear in patients 20-30 years after the onset of the neurodegeneration, when there has been a loss of an essential number of neurons and depletion of compensatory reserves of the brain, which explains the low efficiency of treatment. Therefore, the development of a technology for the diagnosing of Parkinson's disease at the preclinical stage is of a high priority in neurology. In this study, we have developed at an experimental model a fundamentally novel for neurology approach for diagnosis of Parkinson's disease at the preclinical stage. This methodology, widely used for the diagnosis of chronic diseases in the internal medicine, is based on the application of a challenge test that temporarily increases the latent failure of a specific functional system, thereby inducing the short-term appearance of clinical symptoms. The provocation test was developed by a systemic administration of α-methyl-p-tyrosine (αMpT), a reversible inhibitor of tyrosine hydroxylase to MPTP-treated mice at the presymptomatic stage of parkinsonism. For this, we first selected a minimum dose of αMpT, which caused a decrease of the dopamine level in the striatum of normal mice below the threshold at which motor dysfunctions appear. Then, we found the maximum dose of αMpT at which a loss of dopamine in the striatum of normal mice did not reach the threshold level, and motor behavior was not impaired. We showed that αMpT at this dose induced a decrease of the dopamine concentration in the striatum of MPTP-treated mice at the presymptomatic stage of parkinsonism below a threshold level that results in the impairment of motor behavior. Finally, we proved that αMpT exerts a temporal and reversible influence on the nigrostriatal dopaminergic system of MPTP-treated mice with no long-term side effects on other catecholaminergic systems. Thus, the above experimental data strongly suggest that αMpT-based challenge test might be considered as the provocation test for Parkinson's disease diagnosis at the preclinical stage in the future clinical trials.
authors.affiliation: Laboratory of Neural and Neuroendocrine Regulations, Institute of Developmental Biology RAS, 26 Vavilov St, Moscow, 119334, Russia.
authors.forename: Gulnara R
authors.initials: GR
authors.lastname: Khakimova
authors.affiliation: Laboratory of Neural and Neuroendocrine Regulations, Institute of Developmental Biology RAS, 26 Vavilov St, Moscow, 119334, Russia.
authors.forename: Elena A
authors.initials: EA
authors.lastname: Kozina
authors.affiliation: Laboratory of General Pathology of the Nervous System, Institute of General Pathology and Pathophysiology RAMS, 8 Baltiiskaya St, Moscow, 125315, Russia.
authors.forename: Valerian G
authors.initials: VG
authors.lastname: Kucheryanu
authors.affiliation: Laboratory of Neural and Neuroendocrine Regulations, Institute of Developmental Biology RAS, 26 Vavilov St, Moscow, 119334, Russia. michael.ugrumov@mail.ru.|Department of Psychology, Faculty of Social Sciences, The National Research University Higher School of Economics, 20 Myasnitskaya St, Moscow, 101000, Russia. michael.ugrumov@mail.ru.
authors.forename: Michael V
authors.initials: MV
authors.lastname: Ugrumov
mesh_terms: D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000818:Animals; D002395:Catecholamines / Q000378:metabolism; D042241:Early Diagnosis; D008297:Male; D008810:Mice, Inbred C57BL; D008954:Models, Biological; D009043:Motor Activity; D017072:Neostriatum / Q000187:drug effects / Q000378:metabolism; D009412:Nerve Fibers / Q000187:drug effects / Q000378:metabolism; D010300:Parkinson Disease / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology*; D013378:Substantia Nigra / Q000187:drug effects / Q000378:metabolism; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism; D019805:alpha-Methyltyrosine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D002395:Catecholamines; D019805:alpha-Methyltyrosine; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D014446:Tyrosine 3-Monooxygenase
keywords: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Mice; Motor behavior; Parkinson’s disease; Presymptomatic stage; Tyrosine hydroxylase